	US 12,404,343 B2
	Humanised anti kallikrein-2 antibody
Par Oskar Vilhelmsson Timmermand, Lund (SE); Amanda Thuy Tran, Malmo (SE); Sven-Erik Strand, Lund (SE); Urpo Juhani Lamminmaki, Vanhalinna (FI); and Kjell Sjostrom, Lund (SE)
Assigned to Janssen Biotech, Inc., Horsham, PA (US)
Filed by Janssen Biotech, Inc., Horsham, PA (US)
Filed on Sep. 16, 2021, as Appl. No. 17/476,683.
Application 17/476,683 is a continuation of application No. 16/117,522, filed on Aug. 30, 2018, granted, now 11,230,609.
Application 16/117,522 is a continuation of application No. 15/036,170, granted, now 10,100,125, previously published as PCT/GB2014/053420, filed on Nov. 19, 2014.
Claims priority of application No. 1320408 (GB), filed on Nov. 19, 2013; and application No. 1401973 (GB), filed on Feb. 5, 2014.
Prior Publication US 2022/0064333 A1, Mar. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/40 (2006.01); A61K 39/00 (2006.01); A61K 51/10 (2006.01); C07K 16/30 (2006.01)

CPC C07K 16/40 (2013.01) [A61K 51/1045 (2013.01); A61K 51/1075 (2013.01); A61K 51/1096 (2013.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)]

32 Claims

1. A method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an antibody polypeptide with binding specificity for human kallikrein-2 (hK2), wherein the antibody polypeptide is an intact antibody and comprises

(a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and SEQ ID NO:3; and

(b) a light chain variable region comprising the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 and SEQ ID NO:6,

and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies.